Europlasma shows an atypical stock profile on Euronext Growth Paris in 2026. The group, repositioned towards clean technologies and heavy industry after several recent acquisitions, continues to finance its strategy through convertible bonds. For historical shareholders, the question is no longer whether dilution has occurred, but rather to assess what remains to be expected from a stock whose capital structure has profoundly changed.
Europlasma Capital Dilution: What Regulatory Statements Show
The total number of voting rights and shares comprising the capital is subject to mandatory monthly publications. The one from May 31, 2026, released via EQS News, confirms the continuation of a trend that has been ongoing for several years: the number of shares outstanding continues to increase with each issuance of convertible bonds.
You may also like : What is the best raincoat?
In January 2026, Europlasma drew 400 convertible bonds into new shares for a nominal amount of 2 million euros. A second draw, involving 200 bonds for 1 million euros, followed shortly after. These operations are part of a financing program through OCABSA (convertible bonds with stock warrants), a mechanism that gradually transforms debt into equity.
For a shareholder who held shares before these operations, each conversion mechanically leads to a reduction in their relative stake in the capital. Shareholders who can learn more on Investir Actif will find a detailed breakdown of this mechanism and its practical consequences.
Recommended read : The planned changes for the broadcast of F1 Grand Prix in 2024
Financing through OCABSA: A Structure Under Parliamentary Scrutiny
The use of OCABSA is not only debated on stock forums. An investigative committee of the National Assembly heard, between 2024 and 2025, participants who explicitly criticized the role of Alpha Blue Ocean in financing Europlasma. The fund was presented as using convertible bond mechanisms deemed problematic for minority shareholders.
The Journal des Entreprises published an analysis titled “a new bond financing that raises questions,” highlighting the sustainability of this structure. The total financing committed reached 4.5 million euros for the described tranche, in a context where the stock price had already suffered a significant collapse.
This type of financing is based on a simple principle: the bondholder converts the bonds into shares at a discounted price compared to the market, then sells these shares. The stock faces continuous downward pressure as long as conversions continue. The available data does not allow for a precise determination of the effective average conversion price, but the mechanism is structurally unfavorable to existing shareholders.
Bretagne Foundry and Valdunes: The Industrial Strategy Behind the Stock
Since 2025, Europlasma has been repositioning towards heavy industry, primarily through two assets: Bretagne Foundry and Valdunes Industries. These acquisitions form the foundation of the strategic narrative presented to investors.
Bretagne Foundry, acquired in May 2025, has received 14.5 million euros in contributions since its acquisition, including 12.5 million in capital. Part of this funding comes from a trust with Renault, amounting to 10 million euros. The site experienced a tumultuous week (fire, production halt, extraordinary CSE), after which Europlasma issued a statement reaffirming its commitment.
The foundry is also attempting diversification into the defense industry, presented as a key step. Field reports vary on this point: production has been temporarily suspended, and the process of manufacturing shell bodies remains at the initial stage.
On the Valdunes Industries side, a contract worth 4.3 million dollars for supplying train wheels to the United States was announced in early 2026. This contract provides a concrete commercial signal but represents a modest amount relative to the group’s overall financing needs.
Assets to Evaluate for a Shareholder
- Bretagne Foundry, a historic industrial tool in Morbihan whose profitability remains to be demonstrated after the massive investments made since the acquisition
- Valdunes Industries, positioned in the international railway market with a first American contract signed
- Plasma technology, the group’s historical activity in hazardous waste treatment, whose contribution to recent revenues is not detailed in the latest communications
Europlasma Annual Results 2025: What the June 2026 Publication Reveals
The annual results for 2025, published on June 11, 2026, on Euronext, arrive with a notable delay compared to the end of the fiscal year. This delay, common among small caps undergoing restructuring, complicates decision-making for shareholders seeking updated data.
The publication of these results constitutes the first complete accounting assessment integrating Bretagne Foundry over several months. The 2025 accounts measure for the first time the actual impact of acquisitions on the group’s consolidated perimeter. In the absence of public numerical details beyond the regulatory announcement, it is premature to conclude on the financial trajectory.
What can be observed objectively: the group continues to draw on convertible bonds to finance its ongoing operations, suggesting that cash flows generated by the subsidiaries do not yet cover the needs of the perimeter.
Historical Shareholder of Europlasma: Hold, Strengthen, or Liquidate
The situation in 2026 places historical shareholders in a position of arbitration that goes beyond simply reading a stock price. Several elements structure this choice:
- Past dilution has already significantly reduced the value of each share held before the OCABSA programs
- The industrial strategy relies on tangible assets (foundry, railway), but their profitability has yet to be established
- Financing through convertible bonds is not finished, which suggests further conversions and thus additional dilution
- The political context, with parliamentary hearings on financial structures involving Alpha Blue Ocean, adds reputational risk to the case
No clear catalyst allows for anticipating a turnaround in the stock price in the short term. Shareholders considering holding their position are betting on the group’s ability to transform its industrial acquisitions into cash generators, within a timeline that remains uncertain. Those contemplating liquidation acknowledge a loss but free themselves from the risk of future dilution. The choice depends on individual tolerance for uncertainty and the weight of this line in an overall portfolio.